• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MyCartis launches Evalution, a next generation multiplex biomarker analysis platform

MyCartis launches Evalution, a next generation multiplex biomarker analysis platform

October 9, 2014
CenterWatch Staff

MyCartis, a Switzerland and Belgium-based new company dedicated to changing healthcare through personalization originating from Biocartis’ business unit Evalution and Pronota, has launched Evalution, a multiplex biomarker analysis platform for the life sciences research market.

Evalution is MyCartis’ digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers, delivering high quality data and rapid results. Evalution provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.

Biocartis is a global provider of personalized medicine and Pronota is a developer of diagnostics for early detection of life-threatening conditions and unmet medical needs. The combination of the Evalution platform, as designed by Biocartis, and Pronota’s portfolio of validated biomarkers will deliver state-of-the-art solutions for a range of diseases in the fields of cardiovascular and women's health.

"We believe that every individual has the right to good health. But we know that the current health model of ‘one size fits all’ is unsustainable," said Paul Ladestein, CEO of MyCartis. “By developing biomarker analysis solutions at the forefront of innovation we want to improve healthcare worldwide. Our next generation multiplexing platform Evalution will support researchers to better understand the role of biomarkers in early disease and risk diagnosis and patient management. Evalution can analyze an individual’s protein and molecular profile in a single assay plate.”

MyCartis also engages in licensing opportunities with companies aiming to develop their own commercial applications on the Evalution platform. Furthermore, MyCartis develops and validates novel applications with simpler assay formats and unique biomarkers for a range of diseases.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing